Generic Name and Formulations:
Neisseria meningitidis recombinant lipidated factor H binding protein (fHBP) variants 120mcg of Group B (subfamily A + subfamily B); per 0.5mL; susp for IM inj; contains polysorbate 80.
Indications for TRUMENBA:
Adults and Children:
<10yrs: not established. Give by IM inj in deltoid muscle of upper arm. 10–25yrs: 0.5mL given as 3-dose series according to a 0-, 2-, and 6-month schedule.
Severe allergic reaction after a previous dose of Trumenba.
Have epinephrine inj available. Immunosuppressed. Elderly. Pregnancy (Cat.B). Nursing mothers.
Concomitant other vaccines: see full labeling.
Inj site pain, fatigue, headache, muscle pain, chills, fever.
Single-dose prefilled syringes—5, 10
Endocrinology Advisor Articles
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- Case for Continuous Glucose Monitoring in Youth-Onset Type 2 Diabetes
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Pioglitazone May Reduce Cardiovascular, Noncardiovascular Mortality in T2D
- HbA1c Levels Affect Serum Phospholipids, Inflammation inT2D, CVD
- No Cardiovascular Benefit With Fenofibrate in T2D and Hypertriglyceridemia
- Cardiovascular Function May Improve After Cure of Cushing Syndrome
- Primary Prevention Outcomes With Aspirin in T2D and Heart Failure
- Greater Bone Formation With Teriparatide vs Zoledronic Acid in Osteoporosis